array:23 [
  "pii" => "S000173102400588X"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.05.044"
  "estado" => "S200"
  "fechaPublicacion" => "2024-09-04"
  "aid" => "4032"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "crp"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S0001731024005891"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.045"
    "estado" => "S200"
    "fechaPublicacion" => "2024-09-04"
    "aid" => "4033"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Four-case Report of Upadacitinib as an Alternative Treatment for Patients With Recalcitrant Pyoderma Gangrenosum"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Upadacitinib como alternativa terap&#233;utica en pacientes con pioderma gangrenoso recalcitrante&#58; reporte de cuatro casos"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2347
              "Ancho" => 2333
              "Tamanyo" => 478525
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Pyoderma gangrenosum treated with upadacitinib&#58; &#40;a&#41; case &#35;2 prior to upadacitinib therapy&#59; &#40;b&#41; case &#35;2&#44; 10 weeks after starting upadacitinib&#59; &#40;c&#41; case &#35;3 prior to upadacitinib&#59; &#40;d&#41; case &#35;3&#44; 4 weeks after starting upadacitinib&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#46;J&#46; Melgosa Ramos, R&#46; Garc&#237;a-Ru&#237;z, A&#46; Aguado V&#225;zquez, P&#46; Mercader-Garc&#237;a"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "Melgosa Ramos"
            ]
            1 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Garc&#237;a-Ru&#237;z"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Aguado V&#225;zquez"
            ]
            3 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Mercader-Garc&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005891?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731024005891/v1_202409040421/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "S0001731023004908"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.022"
    "estado" => "S200"
    "fechaPublicacion" => "2023-07-18"
    "aid" => "3547"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Recalcitrant Hailey&#8211;Hailey Disease With Satisfactory Response to Apremilast"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Enfermedad de Hailey-Hailey recalcitrante con respuesta satisfactoria a apremilast"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2049
              "Ancho" => 1555
              "Tamanyo" => 362161
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Red-brown plaques with superficial erosions and a macerated appearance&#44; located in the axillary folds &#40;A&#41; and groin &#40;B&#41; before the start of treatment with apremilast&#46; Note the improvement of the lesions after 6 months of treatment with apremilast 30<span class="elsevierStyleHsp" style=""></span>mg twice a day &#40;C and D&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Mansilla-Polo, C&#46; Abril-P&#233;rez, M&#46;&#193;&#46; Navarro-Mira, R&#46; Botella-Estrada"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Mansilla-Polo"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Abril-P&#233;rez"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Navarro-Mira"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Botella-Estrada"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004908?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731023004908/v1_202307180913/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:17 [
      "pii" => "S0001731024008688"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2024.10.056"
      "estado" => "S5"
      "fechaPublicacion" => "2024-10-24"
      "aid" => "4147"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 0
      "subdocumento" => "crp"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:8 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
        "titulo" => "Mantenimiento a 4 a&#241;os del aclaramiento completo con bimekizumab en 10 pacientes en Espa&#241;a procedentes del estudio BE RADIANT"
        "tienePdf" => "en"
        "tieneTextoCompleto" => 0
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "&#91;&#91;Translated article&#93;&#93;Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial"
          ]
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; L&#243;pez Ferrer, I&#46; Belinch&#243;n Romero, R&#46; Rivera D&#237;az, P&#46; Herranz Pinto"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "L&#243;pez Ferrer"
              ]
              1 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Belinch&#243;n Romero"
              ]
              2 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Rivera D&#237;az"
              ]
              3 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz Pinto"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024008688?idApp=UINPBA000044"
      "url" => "/00017310/unassign/S0001731024008688/v1_202410240442/en/main.assets"
    ]
  ]
  "es" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
    "titulo" => "Mantenimiento a 4 a&#241;os del aclaramiento completo con bimekizumab en 10 pacientes en Espa&#241;a procedentes del estudio BE RADIANT"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sr&#46; Director&#44;</span>"
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "A&#46; L&#243;pez Ferrer, I&#46; Belinch&#243;n Romero, R&#46; Rivera D&#237;az, P&#46; Herranz Pinto"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "L&#243;pez Ferrer"
            "email" => array:1 [
              0 => "alopezfe@santpau.cat"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Belinch&#243;n Romero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Rivera D&#237;az"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz Pinto"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital de la Santa Creu i Sant Pau&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital General Universitario Dr&#46; Balmis&#44; Universidad Miguel Hern&#225;ndez ISABIAL&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario 12 de Octubre&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Bimekizumab es el primer inhibidor dual y selectivo de las isoformas A y F de la interleucina 17 &#40;IL-17&#41;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a>&#46; Bimekizumab est&#225; aprobado para la indicaci&#243;n de psoriasis en placas moderada&#47;grave<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1&#8211;3</span></a> y tiene desarrollo cl&#237;nico fase 3 finalizado en artritis psori&#225;sica<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a>&#44; espondiloartritis axial<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">6</span></a> e hidradenitis supurativa<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a>&#46; Su mecanismo de acci&#243;n innovador ha permitido alcanzar unas tasas de blanqueamiento de la piel en los pacientes que han demostrado superioridad en estudios <span class="elsevierStyleItalic">head-to-head</span> versus adalimumab<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a>&#44; ustekinumab<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> y secukinumab<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>&#46; M&#225;s all&#225; de la superioridad en las comparaciones directas&#44; en el <span class="elsevierStyleItalic">network meta-analysis</span> de Armstrong et al&#46; &#40;2022&#41;&#44; bimekizumab se posiciona como el f&#225;rmaco con una mayor probabilidad de alcanzar las respuestas <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; 75&#44; PASI 90 y PASI 100 de entre todos los tratamientos aprobados para la psoriasis<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a>&#46; El blanqueamiento de la piel con bimekizumab se alcanza de forma r&#225;pida &#40;PASI 90 a semana 4&#58; 45&#44;3&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> y persistente en el tiempo &#40;PASI 90 a semana 104&#58; 89&#44;7-96&#44;9&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El estudio BE RADIANT es un ensayo cl&#237;nico fase 3b aleatorizado en el que se eval&#250;a la eficacia y la seguridad de bimekizumab hasta la semana 48 comparada con secukinumab en pacientes con psoriasis en placas moderada&#47;grave&#46; Los resultados de este ensayo cl&#237;nico indican que la mayor&#237;a de los pacientes con bimekizumab alcanzan el blanqueamiento completo de la piel &#40;reducci&#243;n del 100&#37; del PASI basal&#58; 100&#44; desde la semana 4 hasta la semana 48&#44; demostrando superioridad estad&#237;sticamente significativa &#40;p<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001&#41; frente a secukinumab en todos los objetivos del estudio&#44; tanto primarios como secundarios<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">La finalizaci&#243;n de un ensayo cl&#237;nico implica habitualmente la suspensi&#243;n del f&#225;rmaco en estudio&#46; La continuaci&#243;n del tratamiento postensayo supone una ventaja para los pacientes con buena respuesta y tolerabilidad al f&#225;rmaco&#44; evitando as&#237; agotar una l&#237;nea terap&#233;utica eficaz&#46; En Espa&#241;a se incluyeron 10 pacientes en el estudio BE RADIANT&#46; Una vez finalizado el periodo de extensi&#243;n abierto&#44; los pacientes pudieron mantener el tratamiento con bimekizumab gracias a un programa de acceso postensayo cl&#237;nico por parte del laboratorio comercializador&#46; Los pacientes han continuado en tratamiento con bimekizumab 320<span class="elsevierStyleHsp" style=""></span>mg&#47;cada 8 semanas&#44; con un tiempo de seguimiento de un a&#241;o postensayo&#44; un total de 4 a&#241;os de tratamiento&#46; El objetivo del presente estudio es evaluar la respuesta terap&#233;utica y seguridad a largo plazo de estos pacientes que finalizaron el estudio BE RADIANT en Espa&#241;a y que contin&#250;an en tratamiento con bimekizumab postensayo&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Las caracter&#237;sticas demogr&#225;ficas de los pacientes se detallan en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#46; Se incluyeron un total de 7 varones y 3 mujeres&#44; con una edad media de 46&#44;3 a&#241;os y un &#237;ndice de masa corporal &#40;IMC&#41; medio de 26&#44;1&#46; Dos de los pacientes ten&#237;an antecedentes de artritis psori&#225;sica que no estaba activa en el momento de iniciarse el tratamiento con bimekizumab&#44; ni se detectaron brotes de la enfermedad durante su seguimiento&#46; La mayor&#237;a de los pacientes hab&#237;an realizado tratamiento sist&#233;mico convencional o fototerapia &#40;8&#47;10&#41;&#44; con una media de tratamientos previos de 1&#44;5&#44; siendo el metotrexato el f&#225;rmaco m&#225;s utilizado en 7&#47;10 pacientes&#44; seguido de ciclosporina y fototerapia en 3&#47;10&#44; y acitretina en 2&#47;10 pacientes&#46; En 9&#47;10 casos los pacientes eran <span class="elsevierStyleItalic">na&#239;ve</span> a tratamiento biol&#243;gico y un paciente hab&#237;a recibido adalimumab previamente a su entrada en el ensayo cl&#237;nico&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">Todos los pacientes presentaban un PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0 al finalizar el estudio BE RADIANT&#46; En el seguimiento postensayo&#44; el 100&#37; de los pacientes mantuvieron el aclaramiento completo de la piel &#40;PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#41; a los 6 y 12 meses &#40;despu&#233;s de 3&#44;5 y 4 a&#241;os de tratamiento con bimekizumab&#44; respectivamente&#41;&#46; Ninguno de los pacientes present&#243; afectaci&#243;n ungueal&#44; del cuero cabelludo o palmoplantar durante el seguimiento a 6 y 12 meses&#46; Ninguno de los pacientes refiri&#243; impacto de la psoriasis en su calidad de vida ni a los 6 ni a los 12 meses de seguimiento postensayo&#46; El 100&#37; de los pacientes presentaron un <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41;<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46; En todos los casos&#44; bimekizumab fue bien tolerado y no se detectaron nuevas alertas de seguridad en el seguimiento postensayo&#46; Dos de los pacientes presentaron candidiasis oral leve que no supuso la discontinuaci&#243;n del tratamiento y se manej&#243; con terapia antif&#250;ngica habitual&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Teniendo en cuenta la reciente aprobaci&#243;n de bimekizumab por parte de las agencias reguladoras&#44; la evidencia del f&#225;rmaco en pr&#225;ctica cl&#237;nica real es limitada y est&#225; basada en el reporte de casos&#46; Con el presente trabajo de seguimiento postensayo&#44; presentamos la primera serie de pacientes tratados con bimekizumab en condiciones de pr&#225;ctica cl&#237;nica habitual&#46; Los 10 pacientes espa&#241;oles incluidos en el estudio BE RADIANT consiguieron una respuesta completa precoz y persistente con un perfil de seguridad favorable a los 4 a&#241;os&#44; el mayor tiempo de seguimiento publicado hasta la fecha&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Autor&#237;as</span><p id="par0035" class="elsevierStylePara elsevierViewall">ALF&#44; IBR&#44; RR y PH han participado en&#58; la concepci&#243;n y el dise&#241;o del estudio&#44; o la adquisici&#243;n de datos&#44; o el an&#225;lisis y la interpretaci&#243;n de los datos&#59; el borrador del art&#237;culo o la revisi&#243;n cr&#237;tica del contenido intelectual&#44; y la aprobaci&#243;n definitiva de la versi&#243;n que se presenta&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicto de intereses</span><p id="par0040" class="elsevierStylePara elsevierViewall">ALF ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para UCB&#44; AbbVie&#44; Almirall&#44; Janssen&#44; Novartis&#44; Lilly y Leo Pharma&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">IBR ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para de Pfizer-Wyeth&#59; Janssen Pharmaceuticals Inc&#44; MSD&#44; Almirall SA&#44; Lilly&#44; Leo-Pharma&#44; AbbVie&#44; Novartis y UCB&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">RR ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para UCB&#44; AbbVie&#44; Almirall&#44; Boehringer&#44; Janssen&#44; Novartis&#44; Lilly y Leo Pharma&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">PH ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigador de ensayos cl&#237;nicos para AbbVie&#44; Almirall&#44; Janssen&#44; Novartis&#44; Lilly&#44; Leo Pharma&#44; Pfizer&#44; Sanofi y UCB&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:3 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Autor&#237;as"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Conflicto de intereses"
        ]
        2 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">DE&#58; desviaci&#243;n est&#225;ndar&#59; IMC&#58; &#237;ndice de masa corporal&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sexo &#40;varones&#47;mujeres&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 varones&#47;3 mujeres&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Edad &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41; a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46&#44;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>15&#44;7 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26&#44;1<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&#241;os evoluci&#243;n psoriasis &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#44;6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&#44;2 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tratamiento sist&#233;mico previo o fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#250;mero de tratamientos previos &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#44;5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tratamiento biol&#243;gico previo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;adalimumab&#41;&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3643119.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas de los pacientes</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab efficacy and safety in moderate to severe plaque psoriasis &#40;BE READY&#41;&#58; A multicentre&#44; double-blind&#44; placebo-controlled&#44; randomised withdrawal phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;B&#46; Gordon"
                            1 => "P&#46; Foley"
                            2 => "J&#46;G&#46; Krueger"
                            3 => "A&#46; Pinter"
                            4 => "K&#46; Reich"
                            5 => "R&#46; Vender"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00126-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "475"
                        "paginaFinal" => "486"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33549192"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis &#40;BE VIVID&#41;&#58; Efficacy and safety from a 52-week&#44; multicentre&#44; double-blind&#44; active comparator and placebo controlled phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "K&#46;A&#46; Papp"
                            2 => "A&#46; Blauvelt"
                            3 => "R&#46;G&#46; Langley"
                            4 => "A&#46; Armstrong"
                            5 => "R&#46;B&#46; Warren"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00125-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "487"
                        "paginaFinal" => "498"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33549193"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus Adalimumab in Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;B&#46; Warren"
                            1 => "A&#46; Blauvelt"
                            2 => "J&#46; Bagel"
                            3 => "K&#46;A&#46; Papp"
                            4 => "P&#46; Yamauchi"
                            5 => "A&#46; Armstrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/nejmoa2102388"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "385"
                        "paginaInicial" => "130"
                        "paginaFinal" => "141"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33891379"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab in patients with psoriatic arthritis&#44; naive to biologic treatment&#58; A randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial &#40;BE OPTIMAL&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46;B&#46; McInnes"
                            1 => "A&#46; Asahina"
                            2 => "L&#46;C&#46; Coates"
                            3 => "R&#46; Landew&#233;"
                            4 => "J&#46;F&#46; Merola"
                            5 => "C&#46;T&#46; Ritchlin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(22)02302-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2023"
                        "volumen" => "401"
                        "paginaInicial" => "25"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36493791"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-&#945; inhibitors&#58; A randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial &#40;BE COMPLETE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;F&#46; Merola"
                            1 => "R&#46; Landew&#233;"
                            2 => "I&#46;B&#46; McInnes"
                            3 => "P&#46;J&#46; Mease"
                            4 => "C&#46;T&#46; Ritchlin"
                            5 => "Y&#46; Tanaka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(22)02303-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2023"
                        "volumen" => "401"
                        "paginaInicial" => "38"
                        "paginaFinal" => "48"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36495881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of bimekizumab in axial spondyloarthritis&#58; Results of two parallel phase 3 randomised controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Van Der Heijde"
                            1 => "A&#46; Deodhar"
                            2 => "X&#46; Baraliakos"
                            3 => "M&#46;A&#46; Brown"
                            4 => "H&#46; Dobashi"
                            5 => "M&#46; Dougados"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard-2022-223595"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2023"
                        "volumen" => "82"
                        "paginaInicial" => "515"
                        "paginaFinal" => "526"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36649967"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa&#58; A Phase 2&#44; Double-blind Placebo-Controlled Randomized Clinical Trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Glatt"
                            1 => "G&#46;B&#46;E&#46; Jemec"
                            2 => "S&#46; Forman"
                            3 => "C&#46; Sayed"
                            4 => "G&#46; Schmieder"
                            5 => "J&#46; Weisman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.2905"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1279"
                        "paginaFinal" => "1288"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34406364"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus Secukinumab in Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "R&#46;B&#46; Warren"
                            2 => "M&#46; Lebwohl"
                            3 => "M&#46; Gooderham"
                            4 => "B&#46; Strober"
                            5 => "R&#46;G&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/nejmoa2102383"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "385"
                        "paginaInicial" => "142"
                        "paginaFinal" => "152"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33891380"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis&#58; A Systematic Literature Review and a Network Meta-Analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Armstrong"
                            1 => "K&#46; Fahrbach"
                            2 => "C&#46; Leonardi"
                            3 => "M&#46; Augustin"
                            4 => "B&#46; Neupane"
                            5 => "P&#46; Kazmierska"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13555-022-00760-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther &#40;Heidelb&#41;"
                        "fecha" => "2022"
                        "volumen" => "12"
                        "paginaInicial" => "1777"
                        "paginaFinal" => "1792"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35798920"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of bimekizumab through 2 years in patients with moderate-To-severe plaque psoriasis&#58; Longer-Term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Tha&#231;i"
                            1 => "R&#46; Vender"
                            2 => "M&#46;A&#46; de Rie"
                            3 => "C&#46; Conrad"
                            4 => "D&#46;M&#46; Pariser"
                            5 => "B&#46; Strober"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac021"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "22"
                        "paginaFinal" => "31"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36689515"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/unassign/S000173102400588X/v1_202409040421/es/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00017310/unassign/S000173102400588X/v1_202409040421/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102400588X?idApp=UINPBA000044"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Carta científico-clínica
Mantenimiento a 4 años del aclaramiento completo con bimekizumab en 10 pacientes en España procedentes del estudio BE RADIANT
Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial
A. López Ferrera,
Corresponding author
alopezfe@santpau.cat

Autor para correspondencia.
, I. Belinchón Romerob, R. Rivera Díazc, P. Herranz Pintod
a Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
b Servicio de Dermatología, Hospital General Universitario Dr. Balmis, Universidad Miguel Hernández ISABIAL, Alicante, España
c Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
d Servicio de Dermatología, Hospital Universitario La Paz, Madrid, España
Read
808
Times
was read the article
282
Total PDF
526
Total HTML
Share statistics
 array:23 [
  "pii" => "S000173102400588X"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.05.044"
  "estado" => "S200"
  "fechaPublicacion" => "2024-09-04"
  "aid" => "4032"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "crp"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S0001731024005891"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.045"
    "estado" => "S200"
    "fechaPublicacion" => "2024-09-04"
    "aid" => "4033"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Four-case Report of Upadacitinib as an Alternative Treatment for Patients With Recalcitrant Pyoderma Gangrenosum"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Upadacitinib como alternativa terap&#233;utica en pacientes con pioderma gangrenoso recalcitrante&#58; reporte de cuatro casos"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2347
              "Ancho" => 2333
              "Tamanyo" => 478525
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Pyoderma gangrenosum treated with upadacitinib&#58; &#40;a&#41; case &#35;2 prior to upadacitinib therapy&#59; &#40;b&#41; case &#35;2&#44; 10 weeks after starting upadacitinib&#59; &#40;c&#41; case &#35;3 prior to upadacitinib&#59; &#40;d&#41; case &#35;3&#44; 4 weeks after starting upadacitinib&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#46;J&#46; Melgosa Ramos, R&#46; Garc&#237;a-Ru&#237;z, A&#46; Aguado V&#225;zquez, P&#46; Mercader-Garc&#237;a"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "Melgosa Ramos"
            ]
            1 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Garc&#237;a-Ru&#237;z"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Aguado V&#225;zquez"
            ]
            3 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Mercader-Garc&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024005891?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731024005891/v1_202409040421/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "S0001731023004908"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.05.022"
    "estado" => "S200"
    "fechaPublicacion" => "2023-07-18"
    "aid" => "3547"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>"
      "titulo" => "Recalcitrant Hailey&#8211;Hailey Disease With Satisfactory Response to Apremilast"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Enfermedad de Hailey-Hailey recalcitrante con respuesta satisfactoria a apremilast"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2049
              "Ancho" => 1555
              "Tamanyo" => 362161
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Red-brown plaques with superficial erosions and a macerated appearance&#44; located in the axillary folds &#40;A&#41; and groin &#40;B&#41; before the start of treatment with apremilast&#46; Note the improvement of the lesions after 6 months of treatment with apremilast 30<span class="elsevierStyleHsp" style=""></span>mg twice a day &#40;C and D&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Mansilla-Polo, C&#46; Abril-P&#233;rez, M&#46;&#193;&#46; Navarro-Mira, R&#46; Botella-Estrada"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Mansilla-Polo"
            ]
            1 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Abril-P&#233;rez"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Navarro-Mira"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Botella-Estrada"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023004908?idApp=UINPBA000044"
    "url" => "/00017310/unassign/S0001731023004908/v1_202307180913/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:17 [
      "pii" => "S0001731024008688"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2024.10.056"
      "estado" => "S5"
      "fechaPublicacion" => "2024-10-24"
      "aid" => "4147"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 0
      "subdocumento" => "crp"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:8 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
        "titulo" => "Mantenimiento a 4 a&#241;os del aclaramiento completo con bimekizumab en 10 pacientes en Espa&#241;a procedentes del estudio BE RADIANT"
        "tienePdf" => "en"
        "tieneTextoCompleto" => 0
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "&#91;&#91;Translated article&#93;&#93;Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial"
          ]
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "A&#46; L&#243;pez Ferrer, I&#46; Belinch&#243;n Romero, R&#46; Rivera D&#237;az, P&#46; Herranz Pinto"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "L&#243;pez Ferrer"
              ]
              1 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Belinch&#243;n Romero"
              ]
              2 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Rivera D&#237;az"
              ]
              3 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz Pinto"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024008688?idApp=UINPBA000044"
      "url" => "/00017310/unassign/S0001731024008688/v1_202410240442/en/main.assets"
    ]
  ]
  "es" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fico-cl&#237;nica</span>"
    "titulo" => "Mantenimiento a 4 a&#241;os del aclaramiento completo con bimekizumab en 10 pacientes en Espa&#241;a procedentes del estudio BE RADIANT"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sr&#46; Director&#44;</span>"
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "A&#46; L&#243;pez Ferrer, I&#46; Belinch&#243;n Romero, R&#46; Rivera D&#237;az, P&#46; Herranz Pinto"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "A&#46;"
            "apellidos" => "L&#243;pez Ferrer"
            "email" => array:1 [
              0 => "alopezfe@santpau.cat"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Belinch&#243;n Romero"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Rivera D&#237;az"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz Pinto"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital de la Santa Creu i Sant Pau&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital General Universitario Dr&#46; Balmis&#44; Universidad Miguel Hern&#225;ndez ISABIAL&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario 12 de Octubre&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Bimekizumab es el primer inhibidor dual y selectivo de las isoformas A y F de la interleucina 17 &#40;IL-17&#41;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a>&#46; Bimekizumab est&#225; aprobado para la indicaci&#243;n de psoriasis en placas moderada&#47;grave<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1&#8211;3</span></a> y tiene desarrollo cl&#237;nico fase 3 finalizado en artritis psori&#225;sica<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a>&#44; espondiloartritis axial<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">6</span></a> e hidradenitis supurativa<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a>&#46; Su mecanismo de acci&#243;n innovador ha permitido alcanzar unas tasas de blanqueamiento de la piel en los pacientes que han demostrado superioridad en estudios <span class="elsevierStyleItalic">head-to-head</span> versus adalimumab<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a>&#44; ustekinumab<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> y secukinumab<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>&#46; M&#225;s all&#225; de la superioridad en las comparaciones directas&#44; en el <span class="elsevierStyleItalic">network meta-analysis</span> de Armstrong et al&#46; &#40;2022&#41;&#44; bimekizumab se posiciona como el f&#225;rmaco con una mayor probabilidad de alcanzar las respuestas <span class="elsevierStyleItalic">Psoriasis Area and Severity Index</span> &#40;PASI&#41; 75&#44; PASI 90 y PASI 100 de entre todos los tratamientos aprobados para la psoriasis<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a>&#46; El blanqueamiento de la piel con bimekizumab se alcanza de forma r&#225;pida &#40;PASI 90 a semana 4&#58; 45&#44;3&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> y persistente en el tiempo &#40;PASI 90 a semana 104&#58; 89&#44;7-96&#44;9&#37;&#41;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El estudio BE RADIANT es un ensayo cl&#237;nico fase 3b aleatorizado en el que se eval&#250;a la eficacia y la seguridad de bimekizumab hasta la semana 48 comparada con secukinumab en pacientes con psoriasis en placas moderada&#47;grave&#46; Los resultados de este ensayo cl&#237;nico indican que la mayor&#237;a de los pacientes con bimekizumab alcanzan el blanqueamiento completo de la piel &#40;reducci&#243;n del 100&#37; del PASI basal&#58; 100&#44; desde la semana 4 hasta la semana 48&#44; demostrando superioridad estad&#237;sticamente significativa &#40;p<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001&#41; frente a secukinumab en todos los objetivos del estudio&#44; tanto primarios como secundarios<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">La finalizaci&#243;n de un ensayo cl&#237;nico implica habitualmente la suspensi&#243;n del f&#225;rmaco en estudio&#46; La continuaci&#243;n del tratamiento postensayo supone una ventaja para los pacientes con buena respuesta y tolerabilidad al f&#225;rmaco&#44; evitando as&#237; agotar una l&#237;nea terap&#233;utica eficaz&#46; En Espa&#241;a se incluyeron 10 pacientes en el estudio BE RADIANT&#46; Una vez finalizado el periodo de extensi&#243;n abierto&#44; los pacientes pudieron mantener el tratamiento con bimekizumab gracias a un programa de acceso postensayo cl&#237;nico por parte del laboratorio comercializador&#46; Los pacientes han continuado en tratamiento con bimekizumab 320<span class="elsevierStyleHsp" style=""></span>mg&#47;cada 8 semanas&#44; con un tiempo de seguimiento de un a&#241;o postensayo&#44; un total de 4 a&#241;os de tratamiento&#46; El objetivo del presente estudio es evaluar la respuesta terap&#233;utica y seguridad a largo plazo de estos pacientes que finalizaron el estudio BE RADIANT en Espa&#241;a y que contin&#250;an en tratamiento con bimekizumab postensayo&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Las caracter&#237;sticas demogr&#225;ficas de los pacientes se detallan en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#46; Se incluyeron un total de 7 varones y 3 mujeres&#44; con una edad media de 46&#44;3 a&#241;os y un &#237;ndice de masa corporal &#40;IMC&#41; medio de 26&#44;1&#46; Dos de los pacientes ten&#237;an antecedentes de artritis psori&#225;sica que no estaba activa en el momento de iniciarse el tratamiento con bimekizumab&#44; ni se detectaron brotes de la enfermedad durante su seguimiento&#46; La mayor&#237;a de los pacientes hab&#237;an realizado tratamiento sist&#233;mico convencional o fototerapia &#40;8&#47;10&#41;&#44; con una media de tratamientos previos de 1&#44;5&#44; siendo el metotrexato el f&#225;rmaco m&#225;s utilizado en 7&#47;10 pacientes&#44; seguido de ciclosporina y fototerapia en 3&#47;10&#44; y acitretina en 2&#47;10 pacientes&#46; En 9&#47;10 casos los pacientes eran <span class="elsevierStyleItalic">na&#239;ve</span> a tratamiento biol&#243;gico y un paciente hab&#237;a recibido adalimumab previamente a su entrada en el ensayo cl&#237;nico&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">Todos los pacientes presentaban un PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0 al finalizar el estudio BE RADIANT&#46; En el seguimiento postensayo&#44; el 100&#37; de los pacientes mantuvieron el aclaramiento completo de la piel &#40;PASI<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#41; a los 6 y 12 meses &#40;despu&#233;s de 3&#44;5 y 4 a&#241;os de tratamiento con bimekizumab&#44; respectivamente&#41;&#46; Ninguno de los pacientes present&#243; afectaci&#243;n ungueal&#44; del cuero cabelludo o palmoplantar durante el seguimiento a 6 y 12 meses&#46; Ninguno de los pacientes refiri&#243; impacto de la psoriasis en su calidad de vida ni a los 6 ni a los 12 meses de seguimiento postensayo&#46; El 100&#37; de los pacientes presentaron un <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41;<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46; En todos los casos&#44; bimekizumab fue bien tolerado y no se detectaron nuevas alertas de seguridad en el seguimiento postensayo&#46; Dos de los pacientes presentaron candidiasis oral leve que no supuso la discontinuaci&#243;n del tratamiento y se manej&#243; con terapia antif&#250;ngica habitual&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Teniendo en cuenta la reciente aprobaci&#243;n de bimekizumab por parte de las agencias reguladoras&#44; la evidencia del f&#225;rmaco en pr&#225;ctica cl&#237;nica real es limitada y est&#225; basada en el reporte de casos&#46; Con el presente trabajo de seguimiento postensayo&#44; presentamos la primera serie de pacientes tratados con bimekizumab en condiciones de pr&#225;ctica cl&#237;nica habitual&#46; Los 10 pacientes espa&#241;oles incluidos en el estudio BE RADIANT consiguieron una respuesta completa precoz y persistente con un perfil de seguridad favorable a los 4 a&#241;os&#44; el mayor tiempo de seguimiento publicado hasta la fecha&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Autor&#237;as</span><p id="par0035" class="elsevierStylePara elsevierViewall">ALF&#44; IBR&#44; RR y PH han participado en&#58; la concepci&#243;n y el dise&#241;o del estudio&#44; o la adquisici&#243;n de datos&#44; o el an&#225;lisis y la interpretaci&#243;n de los datos&#59; el borrador del art&#237;culo o la revisi&#243;n cr&#237;tica del contenido intelectual&#44; y la aprobaci&#243;n definitiva de la versi&#243;n que se presenta&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicto de intereses</span><p id="par0040" class="elsevierStylePara elsevierViewall">ALF ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para UCB&#44; AbbVie&#44; Almirall&#44; Janssen&#44; Novartis&#44; Lilly y Leo Pharma&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">IBR ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para de Pfizer-Wyeth&#59; Janssen Pharmaceuticals Inc&#44; MSD&#44; Almirall SA&#44; Lilly&#44; Leo-Pharma&#44; AbbVie&#44; Novartis y UCB&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">RR ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigadora de ensayos cl&#237;nicos para UCB&#44; AbbVie&#44; Almirall&#44; Boehringer&#44; Janssen&#44; Novartis&#44; Lilly y Leo Pharma&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">PH ha recibido honorarios como ponente&#44; en asesor&#237;as y en participaci&#243;n como investigador de ensayos cl&#237;nicos para AbbVie&#44; Almirall&#44; Janssen&#44; Novartis&#44; Lilly&#44; Leo Pharma&#44; Pfizer&#44; Sanofi y UCB&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:3 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Autor&#237;as"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Conflicto de intereses"
        ]
        2 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">DE&#58; desviaci&#243;n est&#225;ndar&#59; IMC&#58; &#237;ndice de masa corporal&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sexo &#40;varones&#47;mujeres&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 varones&#47;3 mujeres&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Edad &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41; a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46&#44;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>15&#44;7 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IMC &#40;kg&#47;m<span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">26&#44;1<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Artritis psori&#225;sica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&#241;os evoluci&#243;n psoriasis &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#44;6<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>6&#44;2 a&#241;os&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tratamiento sist&#233;mico previo o fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#250;mero de tratamientos previos &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#44;5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tratamiento biol&#243;gico previo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;adalimumab&#41;&#47;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3643119.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas de los pacientes</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab efficacy and safety in moderate to severe plaque psoriasis &#40;BE READY&#41;&#58; A multicentre&#44; double-blind&#44; placebo-controlled&#44; randomised withdrawal phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;B&#46; Gordon"
                            1 => "P&#46; Foley"
                            2 => "J&#46;G&#46; Krueger"
                            3 => "A&#46; Pinter"
                            4 => "K&#46; Reich"
                            5 => "R&#46; Vender"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00126-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "475"
                        "paginaFinal" => "486"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33549192"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis &#40;BE VIVID&#41;&#58; Efficacy and safety from a 52-week&#44; multicentre&#44; double-blind&#44; active comparator and placebo controlled phase 3 trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "K&#46;A&#46; Papp"
                            2 => "A&#46; Blauvelt"
                            3 => "R&#46;G&#46; Langley"
                            4 => "A&#46; Armstrong"
                            5 => "R&#46;B&#46; Warren"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(21)00125-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2021"
                        "volumen" => "397"
                        "paginaInicial" => "487"
                        "paginaFinal" => "498"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33549193"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus Adalimumab in Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;B&#46; Warren"
                            1 => "A&#46; Blauvelt"
                            2 => "J&#46; Bagel"
                            3 => "K&#46;A&#46; Papp"
                            4 => "P&#46; Yamauchi"
                            5 => "A&#46; Armstrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/nejmoa2102388"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "385"
                        "paginaInicial" => "130"
                        "paginaFinal" => "141"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33891379"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab in patients with psoriatic arthritis&#44; naive to biologic treatment&#58; A randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial &#40;BE OPTIMAL&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46;B&#46; McInnes"
                            1 => "A&#46; Asahina"
                            2 => "L&#46;C&#46; Coates"
                            3 => "R&#46; Landew&#233;"
                            4 => "J&#46;F&#46; Merola"
                            5 => "C&#46;T&#46; Ritchlin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(22)02302-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2023"
                        "volumen" => "401"
                        "paginaInicial" => "25"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36493791"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-&#945; inhibitors&#58; A randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial &#40;BE COMPLETE&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;F&#46; Merola"
                            1 => "R&#46; Landew&#233;"
                            2 => "I&#46;B&#46; McInnes"
                            3 => "P&#46;J&#46; Mease"
                            4 => "C&#46;T&#46; Ritchlin"
                            5 => "Y&#46; Tanaka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(22)02303-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2023"
                        "volumen" => "401"
                        "paginaInicial" => "38"
                        "paginaFinal" => "48"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36495881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of bimekizumab in axial spondyloarthritis&#58; Results of two parallel phase 3 randomised controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Van Der Heijde"
                            1 => "A&#46; Deodhar"
                            2 => "X&#46; Baraliakos"
                            3 => "M&#46;A&#46; Brown"
                            4 => "H&#46; Dobashi"
                            5 => "M&#46; Dougados"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard-2022-223595"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2023"
                        "volumen" => "82"
                        "paginaInicial" => "515"
                        "paginaFinal" => "526"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36649967"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa&#58; A Phase 2&#44; Double-blind Placebo-Controlled Randomized Clinical Trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Glatt"
                            1 => "G&#46;B&#46;E&#46; Jemec"
                            2 => "S&#46; Forman"
                            3 => "C&#46; Sayed"
                            4 => "G&#46; Schmieder"
                            5 => "J&#46; Weisman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2021.2905"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1279"
                        "paginaFinal" => "1288"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34406364"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bimekizumab versus Secukinumab in Plaque Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "R&#46;B&#46; Warren"
                            2 => "M&#46; Lebwohl"
                            3 => "M&#46; Gooderham"
                            4 => "B&#46; Strober"
                            5 => "R&#46;G&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/nejmoa2102383"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2021"
                        "volumen" => "385"
                        "paginaInicial" => "142"
                        "paginaFinal" => "152"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33891380"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis&#58; A Systematic Literature Review and a Network Meta-Analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Armstrong"
                            1 => "K&#46; Fahrbach"
                            2 => "C&#46; Leonardi"
                            3 => "M&#46; Augustin"
                            4 => "B&#46; Neupane"
                            5 => "P&#46; Kazmierska"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s13555-022-00760-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Ther &#40;Heidelb&#41;"
                        "fecha" => "2022"
                        "volumen" => "12"
                        "paginaInicial" => "1777"
                        "paginaFinal" => "1792"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35798920"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of bimekizumab through 2 years in patients with moderate-To-severe plaque psoriasis&#58; Longer-Term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Tha&#231;i"
                            1 => "R&#46; Vender"
                            2 => "M&#46;A&#46; de Rie"
                            3 => "C&#46; Conrad"
                            4 => "D&#46;M&#46; Pariser"
                            5 => "B&#46; Strober"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac021"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "22"
                        "paginaFinal" => "31"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36689515"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/unassign/S000173102400588X/v1_202409040421/es/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00017310/unassign/S000173102400588X/v1_202409040421/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102400588X?idApp=UINPBA000044"
]
Article information
ISSN: 00017310
Original language: Spanish
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 19 13 32
2024 October 138 67 205
2024 September 163 63 226
2024 August 155 89 244
2024 July 51 50 101

Follow this link to access the full text of the article

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?